Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.
Launched by BRITANNIA PHARMACEUTICALS LTD. · Jun 29, 2006
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day
- Exclusion Criteria:
- • hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females
About Britannia Pharmaceuticals Ltd.
Britannia Pharmaceuticals Ltd. is a dynamic biopharmaceutical company dedicated to the development and commercialization of innovative therapies that address unmet medical needs in various therapeutic areas. With a focus on respiratory, cardiovascular, and metabolic diseases, Britannia leverages cutting-edge research and development to enhance patient outcomes. Committed to quality and excellence, the company operates in compliance with rigorous regulatory standards and actively collaborates with healthcare professionals and research institutions. Through its robust pipeline of clinical trials, Britannia Pharmaceuticals strives to deliver safe and effective solutions that improve the quality of life for patients around the world.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Richard Weiser, MB, MRCP
Principal Investigator
Swansea Hospital, Swansea, Wales
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials